CSPAM
EW icon

Cary Street Partners Asset Management’s Edwards Lifesciences EW Stock Holding History

Cary Street Partners Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-240
Closed -$19.9K – 257
2023
Q1 		$19.9K Hold
240
– – ﹤0.01% 301
2022
Q4 		$17.9K Hold
240
– – ﹤0.01% 331
2022
Q3 		$20K Buy
+240
New +$23.1K ﹤0.01% 283

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cary Street Partners Asset Management's EW Position: Q2 2023 in Review

Cary Street Partners Asset Management sold out of Edwards Lifesciences (EW) in Q2 2023, closing a stake of 240 shares — an estimated $19.9K sold.

Cary Street Partners Asset Management first reported a position in EW in Q3 2022 and held it in 3 quarters. The position peaked at $20K in Q3 2022. 1,278 funds tracked by Wall St. Rank hold EW as of Q2 2023.

  • Cary Street Partners Asset Management reported no remaining Edwards Lifesciences position as of Q2 2023 after selling out during the quarter.
  • Cary Street Partners Asset Management sold 240 Edwards Lifesciences shares in Q2 2023, an estimated $19.9K.
  • Cary Street Partners Asset Management first reported a position in Edwards Lifesciences in Q3 2022 and held it in 3 quarters.
  • Cary Street Partners Asset Management's Edwards Lifesciences position peaked at $20K in Q3 2022.
  • 1,278 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.